Ryan Tohill is currently an associate director of global competitive intelligence for dermatology and rheumatology at The Janssen Pharmaceutical Companies of Johnson & Johnson, based in Horsham, Pennsylvania. He counts among his varied business specialties project management, statistical forecasting, commercial modeling and primary market research in multiple therapy areas.
Tohill has been with Janssen for over six years, but less than three of those years have been spent in his current role in the United States. He began his services for the pharmaceutical company as business analytics and forecasting manager based in London, England.
Tohill has not lost sight of the fact that his company’s parent organization is among those leading the charge to end the COVID-19 pandemic. He even shared in his LinkedIn account the latest development in J&J’s efforts to get the U.S. Food and Drug Administration’s green light on its single-shot COVID-19 vaccine.
Tohill is not new to the world of medicine and pharmaceutical sciences. He was formerly a member of the board of trustees of the Cystic Fibrosis Trust while still living in the United Kingdom.
Before moving on to his current employer, Tohill was a business analytics manager at the biopharmaceutical company Gilead. He was also at one time a business intelligence commercial analyst at Abbott Laboratories.
Tohill earned his bachelor’s degree in business studies from the University of Ulster in Northern Ireland.